Oligodendroglioma - Pipeline Review, H1 2018

  • ID: 4479896
  • Report
  • 152 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Boehringer Ingelheim GmbH
  • Celldex Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Leadiant Biosciences Inc
  • Pfizer Inc
  • MORE
Oligodendroglioma - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Oligodendroglioma - Pipeline Review, H1 2018, provides an overview of the Oligodendroglioma (Oncology) pipeline landscape.

Oligodendroglioma is a type of glioma (primary glial brain tumor). They often contain mineral deposits (called calcifications), areas of hemorrhage, and/or cysts. The most common symptoms are seizures, headaches, and personality changes. Other symptoms vary by location and size of the tumor. Treatment includes chemotherapy surgery and radiation therapy.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Oligodendroglioma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Oligodendroglioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oligodendroglioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oligodendroglioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 2, 7 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively.

Oligodendroglioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Oligodendroglioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Oligodendroglioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Oligodendroglioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Oligodendroglioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Oligodendroglioma (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Oligodendroglioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Oligodendroglioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Boehringer Ingelheim GmbH
  • Celldex Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Leadiant Biosciences Inc
  • Pfizer Inc
  • MORE
Introduction

Report Coverage

Oligodendroglioma - Overview

Oligodendroglioma - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Oligodendroglioma - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Oligodendroglioma - Companies Involved in Therapeutics Development

AbbVie Inc

AngioChem Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Celldex Therapeutics Inc

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

Immatics Biotechnologies GmbH

Ipsen SA

Leadiant Biosciences Inc

Millennium Pharmaceuticals Inc

Northwest Biotherapeutics Inc

Novartis AG

Pfizer Inc

Tocagen Inc

Oligodendroglioma - Drug Profiles

abemaciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

afatinib dimaleate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alisertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bevacizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDX-1401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dasatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DCVax-L - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

depatuxizumab mafodotin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

flucytosine + TBio-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

flucytosine ER + vocimagene amiretrorepvec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMA-950 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

irinotecan hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

irinotecan hydrochloride + TBio-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nilotinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

p28 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

paclitaxel trevatide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palbociclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

procarbazine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Glioma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligodendroglioma - Dormant Projects

Oligodendroglioma - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Secondary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Oligodendroglioma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Oligodendroglioma - Pipeline by AbbVie Inc, H1 2018

Oligodendroglioma - Pipeline by AngioChem Inc, H1 2018

Oligodendroglioma - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Oligodendroglioma - Pipeline by Bristol-Myers Squibb Co, H1 2018

Oligodendroglioma - Pipeline by Celldex Therapeutics Inc, H1 2018

Oligodendroglioma - Pipeline by Eli Lilly and Co, H1 2018

Oligodendroglioma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Oligodendroglioma - Pipeline by Immatics Biotechnologies GmbH, H1 2018

Oligodendroglioma - Pipeline by Ipsen SA, H1 2018

Oligodendroglioma - Pipeline by Leadiant Biosciences Inc, H1 2018

Oligodendroglioma - Pipeline by Millennium Pharmaceuticals Inc, H1 2018

Oligodendroglioma - Pipeline by Northwest Biotherapeutics Inc, H1 2018

Oligodendroglioma - Pipeline by Novartis AG, H1 2018

Oligodendroglioma - Pipeline by Pfizer Inc, H1 2018

Oligodendroglioma - Pipeline by Tocagen Inc, H1 2018

Oligodendroglioma - Dormant Projects, H1 2018

Oligodendroglioma - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Oligodendroglioma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • AngioChem Inc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Celldex Therapeutics Inc
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • Immatics Biotechnologies GmbH
  • Ipsen SA
  • Leadiant Biosciences Inc
  • Millennium Pharmaceuticals Inc
  • Northwest Biotherapeutics Inc
  • Novartis AG
  • Pfizer Inc
  • Tocagen Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll